De Servi et al.2626 De Servi S, Morici N, Boschetti E, et al. Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. Vascul Pharmacol. 2016;80:85-90. http://dx.doi.org/10.1016/j.vph.2015.11.085. PMid:26657879. http://dx.doi.org/10.1016/j.vph.2015.11....
|
2007-2013 |
Observational, retrospective |
314 |
87 |
Median of 104 days with interquartile range (IQR) of 5-365 days for patients on the tirofiban bridge protocol and 105 (IQR: 0–360) for the control group |
Patients on the tirofiban bridge protocol: drug-eluting only (85%); metal only (9.2%); drug-eluting and metal (5.8%) of. In the control group: drug-eluting only (41.4%); metal only (54.2%); drug-eluting and metal (4.4%).p |
Patients on the tirofiban bridge protocol: cardiac (32.2%) and non-cardiac (67.8%). In the control group patients: cardiac (27.8%) and non-cardiac (62.2%). |
NACE at 30 days |
Marcos et al.2828 Marcos EG, Fonseca AC, Hofma SH. Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J. 2011;19(10):412-7. http://dx.doi.org/10.1007/s12471-011-0197-y. PMid:21948020. http://dx.doi.org/10.1007/s12471-011-019...
|
2006-2010 |
Observational, retrospective |
36 |
36 |
Mean of 80 days with standard deviation of 66 days |
Drug-eluting |
Cardiac (42%); non-cardiac (58%) |
MACE at 30 days; hemorrhagic events within 30 days |
Polito et al.3030 Polito MV, Asparago S, Galasso G, et al. Early myocardial surgical revascularization after ST-segment elevation myocardial infarction in multivessel coronary disease: bridge therapy is the solution? J Cardiovasc Med (Hagerstown). 2018;19(3):120-5. http://dx.doi.org/10.2459/JCM.0000000000000621. PMid:29389817. http://dx.doi.org/10.2459/JCM.0000000000...
|
2012-2017 |
Observational, retrospective |
21 |
21 |
Mean of 7.2 days with standard deviation of 3.2 days |
Drug-eluting |
Cardiac |
Complications after surgery, clinical and echocardiographic status, death, reinfarction and/or cardiovascular and non-cardiovascular events over 21.6±15.6 months of follow-up |
Savonitto et al.3131 Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: A phase II study of “bridging” antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104(3):285-91. http://dx.doi.org/10.1093/bja/aep373. PMid:20047898. http://dx.doi.org/10.1093/bja/aep373...
|
- |
Observational, prospective |
30 |
30 |
Median of 4 months with range of 1-12 months |
Drug-eluting |
Cardiac (30%); non-cardiac (70%) |
Cardiovascular death, MI, acute occlusion of the target-lesion demonstrated angiographically while in hospital and need for surgical re-exploration because of bleeding; safety of the treatment |
Xia et al.3434 Xia JG, Qu Y, Shen H, Liu XH. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction. Coron Artery Dis. 2013;24(6):522-6. http://dx.doi.org/10.1097/MCA.0b013e3283645c79. PMid:23900046. http://dx.doi.org/10.1097/MCA.0b013e3283...
|
2011 |
Observational, prospective |
21 |
21 |
Median of 6 months and range of 3-8 months |
Drug-eluting |
Non-cardiac |
cardiovascular Death, MI and target-lesion revascularization from first to third month after hospital discharge; acute left ventricular failure, unstable angina pectoris, adverse hemorrhagic events and severe bleeding from first to third month after hospital discharge |